To ensure better and more specialized management of its subsidiaries, Hitco Holding has established “Dian Darou Tamin Holding.”
Recognizing the distinct nature of certain knowledge-based companies within its portfolio, which exhibit fundamental differences from other subsidiaries of Hitco Holding, the decision has been made to provide separate and specialized guidance and leadership for enhanced management.
Mr. Pejman Shirazian has been appointed as the CEO of Dian Darou Tamin Holding. With his extensive experience and notable expertise in biotechnology and domestic production of cutting-edge pharmaceuticals, he has assumed the leadership role of Dian Holding.
The objective of this initiative is to differentiate the management of companies poised to introduce their innovative medical products and solutions to the market within one to three years. These products are expected to play a significant role in improving the health outcomes of Iranian patients and advancing medical standards.
Some of the subsidiary companies under this holding include:
- Carayakteh Tajhiz Azma: Specializing in gene therapy.
- Novin Darou Zist Fanavar Heraz: Engaged in the production of drugs derived from blood plasma.
- Darou Behbood Tamin: Active in the development of innovative drug delivery systems.
Moving forward, Dian Darou Tamin Holding will operate as a focused entity in the pharmaceutical industry, leveraging the expertise of these leading companies across various domains.
